Uncategorized
Sun Pharma to own Ocular Technologies plus rights to dry eye treatment
Sun Pharmaceutical Industries will acquire Ocular Technologies Sarta, or OTS, the owner of the rights to the dry eye disease treatment Seciera, according to a Sun Pharma press release.Auven Therapeutics, which currently owns OTS, will receive a $40 million upfront payment from Sun Pharma, as well as “contingent developmental milestones and sales milestones,” and tiered royalties based on Seciera sales, the release said.